Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2015, Article ID 896560, 11 pages
http://dx.doi.org/10.1155/2015/896560
Review Article

From Molecular Classification to Targeted Therapeutics: The Changing Face of Systemic Therapy in Metastatic Gastroesophageal Cancer

1Upper Aerodigestive Malignancies Division, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
2Gastroesophageal Cancer Therapeutics Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Room G93, Baltimore, MD 21231, USA

Received 10 November 2014; Accepted 15 January 2015

Academic Editor: Antoni Castells

Copyright © 2015 Adrian Murphy and Ronan J. Kelly. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Siegel, J. Ma, Z. Zou, and A. Jemal, “Cancer statistics, 2014,” CA: Cancer Journal for Clinicians, vol. 64, no. 1, pp. 9–29, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Ferlay, H.-R. Shin, F. Bray, D. Forman, C. Mathers, and D. M. Parkin, “Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008,” International Journal of Cancer, vol. 127, no. 12, pp. 2893–2917, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. K. D. Crew and A. I. Neugut, “Epidemiology of upper gastrointestinal malignancies,” Seminars in Oncology, vol. 31, no. 4, pp. 450–464, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. D. Forman, “An international association between Helicobacter pylori infection and gastric cancer. The EUROGAST Study Group,” The Lancet, vol. 341, no. 8857, pp. 1359–1362, 1993. View at Publisher · View at Google Scholar · View at Scopus
  5. J. H. Rubenstein and J. B. Taylor, “Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux,” Alimentary Pharmacology and Therapeutics, vol. 32, no. 10, pp. 1222–1227, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Hampel, N. S. Abraham, and H. B. El-Serag, “Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications,” Annals of Internal Medicine, vol. 143, no. 3, pp. 199–211, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. D. Cunningham, N. Starling, S. Rao et al., “Capecitabine and oxaliplatin for advanced esophagogastric cancer,” The New England Journal of Medicine, vol. 358, no. 1, pp. 36–46, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. M. J. Overman, S. M. Kazmi, J. Jhamb et al., “Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer,” Cancer, vol. 116, no. 6, pp. 1446–1453, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. N. C. Tebbutt, M. M. Cummins, T. Sourjina et al., “Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial,” British Journal of Cancer, vol. 102, no. 3, pp. 475–481, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. M. A. Shah, S. Shibata, R. G. Stoller et al., “Random assignment multicenter phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF) versus DCF with growth factor support (GCSF) in metastatic gastroesophageal adenocarcinoma (GE),” in ASCO Meeting Abstracts, vol. 28, p. 4014, 2014.
  11. H. E. R. Ford, A. Marshall, J. A. Bridgewater et al., “Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial,” The Lancet Oncology, vol. 15, no. 1, pp. 78–86, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. H. S. Kim, H. J. Kim, S. Y. Kim et al., “Second-line chemotherapy versus supportive cancertreatment in advanced gastric cancer: a meta-analysis,” Annals of Oncology, vol. 24, no. 11, pp. 2850–2854, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Hawkes, A. F. C. Okines, D. Papamichael et al., “Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer,” European Journal of Cancer, vol. 47, no. 8, pp. 1146–1151, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Hironaka, S. Zenda, N. Boku, A. Fukutomi, T. Yoshino, and Y. Onozawa, “Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer,” Gastric Cancer, vol. 9, no. 1, pp. 14–18, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Boussioutas, H. Li, J. Liu et al., “Distinctive patterns of gene expression in premalignant gastric mucosa and gastric cancer,” Cancer Research, vol. 63, no. 10, pp. 2569–2577, 2003. View at Google Scholar · View at Scopus
  16. I. B. Tan, T. Ivanova, K. H. Lim et al., “Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy,” Gastroenterology, vol. 141, no. 2, pp. 476–485, 485 e1–11, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. Z. Lei, I. B. Tan, K. Das et al., “Identification of molecular subtypes of gastric cancer with different responses to pi3-kinase inhibitors and 5-fluorouracil,” Gastroenterology, vol. 145, no. 3, pp. 554–565, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. The Cancer Genome Atlas Research Network, “Comprehensive molecular characterization of gastric adenocarcinoma,” Nature, vol. 513, no. 7517, pp. 202–209, 2014. View at Publisher · View at Google Scholar
  19. J. Gu, J. A. Ajani, E. T. Hawk et al., “Genome-wide catalogue of chromosomal aberrations in Barrett's esophagus and esophageal adenocarcinoma: a high-density single nucleotide polymorphism array analysis,” Cancer Prevention Research, vol. 3, no. 9, pp. 1176–1186, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Varis, P. Puolakkainen, H. Savolainen et al., “DNA copy number profiling in esophageal Barrett adenocarcinoma: comparison with gastric adenocarcinoma and esophageal squamous cell carcinoma,” Cancer Genetics and Cytogenetics, vol. 127, no. 1, pp. 53–58, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. B. J. Reid, L. J. Prevo, P. C. Galipeau et al., “Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression,” The American Journal of Gastroenterology, vol. 96, no. 10, pp. 2839–2848, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. M. C. Hollstein, R. A. Metcalf, J. A. Welsh, R. Montesano, and C. C. Harris, “Frequent mutation of the p53 gene in human esophageal cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 24, pp. 9958–9961, 1990. View at Publisher · View at Google Scholar · View at Scopus
  23. A. G. Casson, T. Mukhopadhyay, K. R. Cleary, J. Y. Ro, B. Levin, and J. A. Roth, “p53 gene mutations in Barrett's epithelium and esophageal cancer,” Cancer Research, vol. 51, no. 16, pp. 4495–4499, 1991. View at Google Scholar · View at Scopus
  24. E. L. Powell, L. M. Leoni, M. I. Canto et al., “Concordant loss of MTAP and p16/CDKN2A expression in gastroesophageal carcinogenesis: evidence of homozygous deletion in esophageal noninvasive precursor lesions and therapeutic implications,” The American Journal of Surgical Pathology, vol. 29, no. 11, pp. 1497–1504, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. M. D. Abeloff, J. C. Eggleston, G. Mendelsohn, D. S. Ettinger, and S. B. Baylin, “Changes in morphologic and biochemical characteristics of small cell carcinoma of the lung. A clinicopathologic study,” The American Journal of Medicine, vol. 66, no. 5, pp. 757–764, 1979. View at Publisher · View at Google Scholar · View at Scopus
  26. N. Agrawal, Y. Jiao, C. Bettegowda et al., “Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma,” Cancer Discovery, vol. 2, no. 10, pp. 899–905, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. A. M. Dulak, S. E. Schumacher, J. van Lieshout et al., “Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis,” Cancer Research, vol. 72, no. 17, pp. 4383–4393, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. M. A. Olayioye, “Update on HER-2 as a target for cancer therapy—intracellular signaling pathways of ErbB2/HER-2 and family members,” Breast Cancer Research, vol. 3, no. 6, pp. 385–389, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Tanner, M. Hollmén, T. T. Junttila et al., “Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab,” Annals of Oncology, vol. 16, no. 2, pp. 273–278, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. D. I. Park, J. W. Yun, J. H. Park et al., “HER-2/neu amplification is an independent prognostic factor in gastric cancer,” Digestive Diseases and Sciences, vol. 51, no. 8, pp. 1371–1379, 2006. View at Publisher · View at Google Scholar
  31. Y. Y. Janjigian, D. Werner, C. Pauligk et al., “Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis,” Annals of Oncology, vol. 23, no. 10, pp. 2656–2662, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. C. Gómez-Martin, E. Garralda, M. J. Echarri et al., “HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer,” Journal of Clinical Pathology, vol. 65, no. 8, pp. 751–757, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. Y.-J. Bang, E. Van Cutsem, A. Feyereislova et al., “Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2- positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial,” The Lancet, vol. 376, no. 9742, pp. 687–697, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Goldhirsch, R. D. Gelber, M. J. Piccart-Gebhart et al., “2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial,” The Lancet, vol. 382, no. 9897, pp. 1021–1028, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. G. von Minckwitz, K. Schwedler, M. Schmidt et al., “Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer,” European Journal of Cancer, vol. 47, no. 15, pp. 2273–2281, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. D. Sakai, T. Satoh, Y. Kurokawa et al., “A phase II trial of trastuzumab combined with irinotecan in patients with advanced HER2-positive chemo-refractory gastric cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group OGSG1203 (HERBIS-5),” Japanese Journal of Clinical Oncology, vol. 43, no. 8, pp. 838–840, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. E. R. Wood, A. T. Truesdale, O. B. McDonald et al., “A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells,” Cancer Research, vol. 64, no. 18, pp. 6652–6659, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. T. Satoh, R.-H. Xu, H. C. Chung et al., “Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN–a randomized, phase III study,” Journal of Clinical Oncology, vol. 32, no. 19, pp. 2039–2049, 2014. View at Publisher · View at Google Scholar
  39. C. W. Adams, D. E. Allison, K. Flagella et al., “Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab,” Cancer Immunology, Immunotherapy, vol. 55, no. 6, pp. 717–727, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. J. Tabernero, P. Marcelo Hoff, L. Shen et al., “Pertuzumab (P) with trastuzumab (T) and chemotherapy (CTX) in patients (pts) with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) cancer: an international phase III study (JACOB),” Journal of Clinical Oncology, 2013, abstr TPS4150. View at Google Scholar
  41. P. M. LoRusso, D. Weiss, E. Guardino, S. Girish, and M. X. Sliwkowski, “Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer,” Clinical Cancer Research, vol. 17, no. 20, pp. 6437–6447, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. H. K. Erickson, P. U. Park, W. C. Widdison et al., “Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing,” Cancer Research, vol. 66, no. 8, pp. 4426–4433, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. UK Clinical Research Network Study Portfolio, “NCRN369: GATSBY TDM1 vs taxane in previously treated advanced HER2+ gastric ca,” UKCRN 12204, http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=12204.
  44. S. K. Muthuswamy, M. Gilman, and J. S. Brugge, “Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers,” Molecular and Cellular Biology, vol. 19, no. 10, pp. 6845–6857, 1999. View at Google Scholar · View at Scopus
  45. C. Chen, J.-M. Yang, T.-T. Hu et al., “Prognostic role of human epidermal growth factor receptor in gastric cancer: a systematic review and meta-analysis,” Archives of Medical Research, vol. 44, no. 5, pp. 380–389, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. L. Zhang, J. Yang, J. Cai et al., “A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy,” Scientific Reports, vol. 3, article 2992, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. E. Van Cutsem, C.-H. Köhne, I. Láng et al., “Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status,” Journal of Clinical Oncology, vol. 29, no. 15, pp. 2011–2019, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. F. Lordick, Y.-K. Kang, H.-C. Chung et al., “Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial,” The Lancet Oncology, vol. 14, no. 6, pp. 490–499, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. T. Waddell, I. Chau, D. Cunningham et al., “Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial,” The Lancet Oncology, vol. 14, no. 6, pp. 481–489, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. S. Rao, N. Starling, D. Cunningham et al., “Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study,” Annals of Oncology, vol. 21, no. 11, pp. 2213–2219, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. T. Inoue, H. Kataoka, K. Goto et al., “Activation of c-Met (hepatocyte growth factor receptor) in human gastric cancer tissue,” Cancer Science, vol. 95, no. 10, pp. 803–808, 2004. View at Publisher · View at Google Scholar · View at Scopus
  52. P. Conrotto, D. Valdembri, S. Corso et al., “Sema4D induces angiogenesis through Met recruitment by Plexin B1,” Blood, vol. 105, no. 11, pp. 4321–4329, 2005. View at Publisher · View at Google Scholar · View at Scopus
  53. T.-J. Huang, J.-Y. Wang, S.-R. Lin, S.-T. Lian, and J.-S. Hsieh, “Overexpression of the c-met protooncogene in human gastric carcinoma—correlation to clinical features,” Acta Oncologica, vol. 40, no. 5, pp. 638–643, 2001. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Yu, Y. Yu, N. Zhao, J. Cui, W. Li, and T. Liu, “c-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis,” PLoS ONE, vol. 8, no. 11, Article ID e79137, 2013. View at Publisher · View at Google Scholar · View at Scopus
  55. T. Iveson, R. C. Donehower, I. Davidenko et al., “Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study,” The Lancet Oncology, vol. 15, no. 9, pp. 1007–1018, 2014. View at Publisher · View at Google Scholar
  56. A Phase 3 Study of Rilotumumab (AMG 102) with Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer (RILOMET-2), NCT02137343, 2014, http://clinicaltrials.gov/show/NCT02137343.
  57. A. Calles, N. Kwiatkowski, B. K. Cammarata, D. Ercan, N. S. Gray, and P. A. Jänne, “Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines,” Molecular Oncology, vol. 9, no. 1, pp. 260–269, 2015. View at Publisher · View at Google Scholar
  58. R. Katayama, A. Aoyama, T. Yamori et al., “Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition,” Cancer Research, vol. 73, no. 10, pp. 3087–3096, 2013. View at Publisher · View at Google Scholar · View at Scopus
  59. Y.-K. Kang, K. Muro, M.-H. Ryu et al., “A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer,” Investigational New Drugs, vol. 32, no. 2, pp. 355–361, 2014. View at Publisher · View at Google Scholar · View at Scopus
  60. N. Ferrara, H.-P. Gerber, and J. LeCouter, “The biology of VEGF and its receptors,” Nature Medicine, vol. 9, no. 6, pp. 669–676, 2003. View at Publisher · View at Google Scholar · View at Scopus
  61. M. A. Shah, R. K. Ramanathan, D. H. Ilson et al., “Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma,” Journal of Clinical Oncology, vol. 24, no. 33, pp. 5201–5206, 2006. View at Publisher · View at Google Scholar · View at Scopus
  62. M. A. Shah, E. Van Cutsem, Y. K. Kang et al., “Survival analysis according to disease subtype in AVAGAST: first-line capecitabine and cisplatin plus bevacizumab (bev) or placebo in patients (pts) with advanced gastric cancer,” Journal of Clinical Oncology, vol. 30, supplement 4, abstract 5, 2012. View at Google Scholar
  63. A. Ohtsu, M. A. Shah, E. van Cutsem et al., “Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study,” Journal of Clinical Oncology, vol. 29, no. 30, pp. 3968–3976, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. C. S. Fuchs, J. Tomasek, C. J. Yong et al., “Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial,” The Lancet, vol. 383, no. 9911, pp. 31–39, 2014. View at Publisher · View at Google Scholar · View at Scopus
  65. H. Wilke, E. van Cutsem, S. C. Oh et al., “RAINBOW: a global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBE),” Journal of Clinical Oncology, vol. 32, supplement 3, 2014, Gastrointestinal Cancers Symposium abstract no. LBA7. View at Google Scholar
  66. H. H. Yoon, J. C. Bendell, F. S. Braiteh et al., “Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): randomized, double-blind, multicenter phase 2 trial,” Journal of Clinical Oncology, vol. 32, no. 5s, 2014, abstr 4004. View at Google Scholar
  67. Y.-J. Bang, Y.-K. Kang, W. K. Kang et al., “Phase II study of sunitinib as second-line treatment for advanced gastric cancer,” Investigational New Drugs, vol. 29, no. 6, pp. 1449–1458, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. J. H. Yi, J. Lee, J. Lee et al., “Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum,” British Journal of Cancer, vol. 106, no. 9, pp. 1469–1474, 2012. View at Publisher · View at Google Scholar · View at Scopus
  69. M. Martin-Richard, R. Gallego, C. Pericay et al., “Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study,” Investigational New Drugs, vol. 31, no. 6, pp. 1573–1579, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. D. J. Wong, E. Segal, and H. Y. Chang, “Stemness, cancer and cancer stem cells,” Cell Cycle, vol. 7, no. 23, pp. 3622–3624, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. M. Hitron, J. Stephenson, K. N. Chi et al., “A phase 1b study of the cancer stem cell inhibitor BBI608 administered with paclitaxel in patients with advanced malignancies,” Journal of Clinical Oncology, vol. 32, supplement, abstract 2530, 2014. View at Google Scholar
  72. R. Bai, H. Zhao, X. Zhang, and S. Du, “Characterization of sonic hedgehog inhibition in gastric carcinoma cells,” Oncology Letters, vol. 7, no. 5, pp. 1381–1384, 2014. View at Publisher · View at Google Scholar · View at Scopus
  73. D. J. Cohen, P. J. Christos, J. A. Sparano et al., “A randomized phase II study of vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: a New York Cancer Consortium led study,” Journal of Clinical Oncology, vol. 31, supplement 4, abstract 67, 2013. View at Google Scholar
  74. C. Yoon, D. J. Park, B. Schmidt et al., “CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance,” Clinical Cancer Research, vol. 20, no. 15, pp. 3974–3988, 2014. View at Publisher · View at Google Scholar
  75. K. Pavelić, T. Kolak, S. Kapitanović et al., “Gastric cancer: the role of insulin-like growth factor 2 (IGF 2) and its receptors (IGF IR and M6-P/IGF 2R),” The Journal of Pathology, vol. 201, no. 3, pp. 430–438, 2003. View at Publisher · View at Google Scholar · View at Scopus
  76. J. Gao, Y. S. Chang, B. Jallal, and J. Viner, “Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology,” Cancer Research, vol. 72, no. 1, pp. 3–12, 2012. View at Publisher · View at Google Scholar · View at Scopus
  77. P. Schöffski, D. Adkins, J.-Y. Blay et al., “An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours,” European Journal of Cancer, vol. 49, no. 15, pp. 3219–3228, 2013. View at Publisher · View at Google Scholar · View at Scopus
  78. S. J. Cohen, Y. Feng, P. J. Catalano et al., “E2208: randomized phase II study of paclitaxel with or without the anti-IGF-IR antibody cixutumumab (IMC-A12) as second-line treatment for patients with metastatic esophageal or GE junction cancer,” Journal of Clinical Oncology, vol. 32, no. 5, supplement, 2014, ASCO Annual Meeting abstract no. 4020. View at Google Scholar
  79. F. A. Barr, H. H. W. Silljé, and E. A. Nigg, “Polo-like kinases and the orchestration of cell division,” Nature Reviews Molecular Cell Biology, vol. 5, no. 6, pp. 429–440, 2004. View at Google Scholar · View at Scopus
  80. B. Spänkuch-Schmitt, G. Wolf, C. Solbach et al., “Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells,” Oncogene, vol. 21, no. 20, pp. 3162–3171, 2002. View at Publisher · View at Google Scholar · View at Scopus
  81. W. Weichert, A. Ullrich, M. Schmidt et al., “Expression patterns of polo-like kinase 1 in human gastric cancer,” Cancer Science, vol. 97, no. 4, pp. 271–276, 2006. View at Publisher · View at Google Scholar · View at Scopus
  82. F. G. de Braud, S. Cascinu, G. Spitaleri et al., “A phase I dose-escalation study of volasertib (BI 6727) combined with nintedanib (BIBF 1120) in advanced solid tumors,” Journal of Clinical Oncology, vol. 31, supplement, abstract 2556, 2013. View at Google Scholar
  83. M. Katoh, “FGF signaling network in the gastrointestinal tract (review),” International Journal of Oncology, vol. 29, no. 1, pp. 163–168, 2006. View at Google Scholar · View at Scopus
  84. H. Murase, M. Inokuchi, Y. Takagi, K. Kato, K. Kojima, and K. Sugihara, “Prognostic significance of the co-overexpression of fibroblast growth factor receptors 1, 2 and 4 in gastric cancer,” Molecular and Clinical Oncology, vol. 2, no. 4, pp. 509–517, 2014. View at Google Scholar
  85. Dovitinib for Gastric Cancer With FGFR2 Amplification, NCT01719549, 2014, http://www.clinicaltrials.gov/ct2/show/NCT01719549?term=fgf+gastric&rank=1.
  86. J. A. Fresno Vara, E. Casado, J. de Castro, P. Cejas, C. Belda-Iniesta, and M. González-Barón, “PI3K/Akt signalling pathway and cancer,” Cancer Treatment Reviews, vol. 30, no. 2, pp. 193–204, 2004. View at Publisher · View at Google Scholar
  87. B. D. Manning and L. C. Cantley, “AKT/PKB signaling: navigating downstream,” Cell, vol. 129, no. 7, pp. 1261–1274, 2007. View at Publisher · View at Google Scholar · View at Scopus
  88. D. C. Fingar, C. J. Richardson, A. R. Tee, L. Cheatham, C. Tsou, and J. Blenis, “mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E,” Molecular and Cellular Biology, vol. 24, no. 1, pp. 200–216, 2004. View at Publisher · View at Google Scholar · View at Scopus
  89. T. Murayama, M. Inokuchi, Y. Takagi et al., “Relation between outcomes and localisation of p-mTOR expression in gastric cancer,” British Journal of Cancer, vol. 100, no. 5, pp. 782–788, 2009. View at Publisher · View at Google Scholar · View at Scopus
  90. S. Velho, C. Oliveira, A. Ferreira et al., “The prevalence of PIK3CA mutations in gastric and colon cancer,” European Journal of Cancer, vol. 41, no. 11, pp. 1649–1654, 2005. View at Publisher · View at Google Scholar · View at Scopus
  91. Y. Sukawa, H. Yamamoto, K. Nosho et al., “Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer,” World Journal of Gastroenterology, vol. 18, no. 45, pp. 6577–6586, 2012. View at Publisher · View at Google Scholar · View at Scopus
  92. M. Li, H. Sun, L. Song, X. Gao, W. Chang, and X. Qin, “Immunohistochemical expression of mTOR negatively correlates with PTEN expression in gastric carcinoma,” Oncology Letters, vol. 4, no. 6, pp. 1213–1218, 2012. View at Publisher · View at Google Scholar · View at Scopus
  93. PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer, NCT01613950, 2014, http://clinicaltrials.gov/show/NCT01613950.
  94. A. Ohtsu, J. A. Ajani, Y.-X. Bai et al., “Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study,” Journal of Clinical Oncology, vol. 31, no. 31, pp. 3935–3943, 2013. View at Publisher · View at Google Scholar · View at Scopus
  95. RAD001 in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer, NCT01049620, 2014, http://clinicaltrials.gov/ct2/show/NCT01049620?term=pi3k+gastric&rank=3.
  96. A Randomized, Double Blind Study Evaluating Paclitaxel with and without RAD001 in Patients with Gastric Carcinoma After Prior Chemotherapy (AIO-STO-0111), NCT01248403, 2014, http://clinicaltrials.gov/show/NCT01248403.
  97. PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma—A 1st Pilot Metastatic Trial of Biologics Beyond Progression, NCT02213289, 2014, http://clinicaltrials.gov/show/NCT02213289.